Open report — full analysis, no account required.

Sign up to generate reports and read filings that aren't on the open list.

Sign up free

Get notified when AVXL files again. Create a free account and we'll email you the moment its next filing is analyzed.

Get filing alerts

Critical incident detected

Governance misconduct

Time-sensitive event — see the red-flag panel below for the source-quoted detail.

Red Flags Detected

  • Departure of CEO (new) — The CEO was terminated for cause by a special committee of independent directors for conduct inconsistent with company policy.
NASDAQ: AVXL ANAVEX LIFE SCIENCES CORP. 8-K

Anavex terminates CEO Christopher Missling for cause, names Terrie Kellmeyer Interim CEO

Filed May 6, 2026 · Period ending April 30, 2026 · ~1 min read

3 key changes 2 high relevance 1 red flag 1 section

Key Changes

  • high

    CEO Christopher Missling was terminated for cause on April 30, 2026, by a special committee of independent directors for conduct inconsistent with company policy. The committee has requested his resignation from the Board.

    Item 5.02 verify on EDGAR →
  • high

    Terrie Kellmeyer, PhD, appointed Interim CEO on May 4, 2026. She brings 30+ years of pharma experience and previously served as the company's SVP of Clinical Development from November 2023 to May 2025.

    Item 5.02 verify on EDGAR →
  • medium

    Kellmeyer's compensation includes $500K base salary, 30% target bonus, $150K signing bonus, and 200,000 stock options to be granted shortly after her start date.

    Item 5.02 verify on EDGAR →

Summary

Anavex Life Sciences terminated CEO Christopher Missling for cause on April 30, 2026, following a special committee investigation that found conduct inconsistent with company policy. The abrupt removal of a long-serving CEO (his employment agreement dates to 2013) by independent directors signals serious governance concerns that retail investors should monitor closely. The company moved quickly to install Terrie Kellmeyer as Interim CEO on May 4.

Kellmeyer's deep pharma background and recent tenure as SVP of Clinical Development suggests continuity in the company's drug development programs, though the 'interim' designation indicates the Board may conduct a broader search. Retail holders should watch for: (1) any additional disclosures about the nature of Missling's termination, (2) whether the company faces legal action from the former CEO, and (3) announcements regarding a permanent CEO search. The lack of detail about the 'cause' creates uncertainty that could pressure the stock until more information emerges.

Section-by-Section Diff

Event · Item 9.01 — Financial Statements and Exhibits

~100 words

Anavex filed an 8-K attaching a press release dated May 6, 2026; no material business event disclosed in the filing body.

1 Added
Show 1 minor / wording change
Added Press release attachment low

Added in current filing · verify on EDGAR →

99.1

Press Release dated May 6, 2026.

The 8-K attaches a press release dated May 6, 2026 as Exhibit 99.1. The filing body does not describe the content of the press release, so the nature and materiality of any disclosed event cannot be determined from this 8-K alone.

Was this report useful?
View original filing on SEC.gov Press release (Ex 99.1) on EDGAR ↗

Figures/quotes linked to EDGAR · Narrative written by AI · Jun 1, 2026 · How we verify